Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Excitingly, in myasthenia [gravis], we have entered the advanced therapy era with the approval of the complement inhibitors starting in 2017, and now, more recently, the FcRn [neonatal Fc receptor ...

1 Department of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China 2 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China Myasthenia gravis (MG) is an ...

1 Department of Neurology, Peking University People’s Hospital, Beijing, China 2 Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China Background: ...

imm.ox.ac.uk Background: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoantibodies directed at the acetylcholine receptor (AChR) on the postsynaptic membrane of ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years, but many patients remain dissatisfied with their disease state despite being on treatment. There is ...

Objective Patients with myasthenia gravis without acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies detected by radioimmunoprecipitation assays (RIAs) are classified as ...

Dropped Head Syndrome (DHS) is a condition characterized by a forward head posture due to weakness in the neck extensor muscles, leading to significant functional impairment. Patients with DHS ...

Chainalysis reported a 35% drop in ransom payments, with ransomware hackers receiving a total of $814 million compared to 2023’s record-high sum of $1.25 billion. In further evidence of ...